Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsIn order to explore the possibility of HLA-mismatched hematopoietic stem cell transplantation from family donors beyond haploidentical relatives, the authors conducted a prospective Phase I/II study of 2-HLA-haplotype-mismatched hematopoietic stem cell transplantation (HSCT).
[Bone Marrow Transplantation]
1254621 U7VMZV2E items 1 apa 0 default asc 1 151004 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-ac2d708532f0abe8fdf4d98d28ea2a38%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22U7VMZV2E%22%2C%22library%22%3A%7B%22id%22%3A1254621%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ikegame%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EIkegame%2C%20K.%2C%20Kaida%2C%20K.%2C%20Fukunaga%2C%20K.%2C%20Osugi%2C%20Y.%2C%20Yoshihara%2C%20K.%2C%20Yoshihara%2C%20S.%2C%20Ishii%2C%20S.%2C%20Fujino%2C%20S.%2C%20Yamashita%2C%20T.%2C%20Mayumi%2C%20A.%2C%20Maruyama%2C%20S.%2C%20Teramoto%2C%20M.%2C%20Inoue%2C%20T.%2C%20Okada%2C%20M.%2C%20Tamaki%2C%20H.%2C%20Ogawa%2C%20H.%2C%20%26amp%3B%20Fujimori%2C%20Y.%20%282020%29.%20Allogeneic%20hematopoietic%20stem%20cell%20transplantation%20from%20a%202-HLA-haplotype-mismatched%20family%20donor%20for%20posttransplant%20relapse%3A%20a%20prospective%20phase%20I%5C%2FII%20study.%20%3Ci%3EBone%20Marrow%20Transplantation%3C%5C%2Fi%3E%2C%201%26%23x2013%3B14.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41409-020-0980-8%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41409-020-0980-8%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D1254621%26amp%3Bitem_key%3DU7VMZV2E%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Allogeneic%20hematopoietic%20stem%20cell%20transplantation%20from%20a%202-HLA-haplotype-mismatched%20family%20donor%20for%20posttransplant%20relapse%3A%20a%20prospective%20phase%20I%5C%2FII%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kazuhiro%22%2C%22lastName%22%3A%22Ikegame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katsuji%22%2C%22lastName%22%3A%22Kaida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keiko%22%2C%22lastName%22%3A%22Fukunaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuko%22%2C%22lastName%22%3A%22Osugi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyoko%22%2C%22lastName%22%3A%22Yoshihara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Satoshi%22%2C%22lastName%22%3A%22Yoshihara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shinichi%22%2C%22lastName%22%3A%22Ishii%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Satoshi%22%2C%22lastName%22%3A%22Fujino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takaya%22%2C%22lastName%22%3A%22Yamashita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azusa%22%2C%22lastName%22%3A%22Mayumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Satoshi%22%2C%22lastName%22%3A%22Maruyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masahiro%22%2C%22lastName%22%3A%22Teramoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takayuki%22%2C%22lastName%22%3A%22Inoue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masaya%22%2C%22lastName%22%3A%22Okada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroya%22%2C%22lastName%22%3A%22Tamaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroyasu%22%2C%22lastName%22%3A%22Ogawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yosihiro%22%2C%22lastName%22%3A%22Fujimori%22%7D%5D%2C%22abstractNote%22%3A%22HLA%20haploidentical%20hematopoietic%20stem%20cell%20transplantation%20%28HSCT%29%2C%20i.e.%2C%20HSCT%20from%20a%201-HLA-haplotype-mismatched%20family%20donor%2C%20has%20been%20successfully%20performed%20even%20as%20a%20second%20transplantation%20for%20posttransplant%20relapse.%20Is%20the%20haploidentical%20the%20limit%20of%20HLA%20mismatches%20in%20HSCT%3F%20In%20order%20to%20explore%20the%20possibility%20of%20HLA-mismatched%20HSCT%20from%20family%20donors%20beyond%20haploidentical%20relatives%2C%20we%20conducted%20a%20prospective%20phase%20I%5C%2FII%20study%20of%202-HLA-haplotype-mismatched%20HSCT%20%282-haplo-mismatch%20HSCT%29.%20We%20enrolled%2030%20patients%20with%20posttransplant%20relapse%20%28acute%20myeloid%20leukemia%3A%2018%2C%20acute%20lymphoblastic%20leukemia%3A%2011%2C%20non-Hodgkin%20lymphoma%3A%201%29.%202-haplo-mismatch%20HSCT%20was%20performed%20as%20the%20second%20to%20sixth%20transplantations.%20The%20donors%20were%20siblings%20%28n%5Cu2009%3D%5Cu200912%29%2C%20cousins%20%28n%5Cu2009%3D%5Cu200916%29%2C%20and%20second%20cousins%20%28n%5Cu2009%3D%5Cu20092%29.%20The%20conditioning%20regimen%20consisted%20of%20fludarabine%2C%20cytarabine%2C%20melphalan%2C%20low-dose%20anti-thymocyte%20globulin%2C%20and%203%5Cu2009Gy%20of%20total%20body%20irradiation.%20Graft-versus-host%20disease%20%28GVHD%29%20prophylaxis%20consisted%20of%20tacrolimus%2C%20methylprednisolone%2C%20and%20mycophenolate%20mofetil.%20All%20patients%20achieved%20neutrophil%20engraftment%2C%20except%20for%20a%20case%20of%20early%20death.%20The%20cumulative%20incidences%20of%20grades%20II%5Cu2013IV%20and%20III%5Cu2013IV%20acute%20GVHD%20were%2036.7%25%20and%2016.7%25%2C%20respectively.%20The%20overall%20survival%20at%201%20year%2C%20relapse%2C%20and%20non-relapse%20mortality%20rates%20was%2030.1%25%2C%2038.9%25%2C%20and%2044.3%25%2C%20respectively.%20Considering%20the%20poor%20prognosis%20of%20posttransplant%20relapse%2C%202-haplo-mismatch%20HSCT%20can%20be%20an%20alternative%20option%20in%20a%20second%20or%20third%20transplantation.%22%2C%22date%22%3A%222020-06-20%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41409-020-0980-8%22%2C%22ISSN%22%3A%221476-5365%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41409-020-0980-8%22%2C%22deleted%22%3A1%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222020-06-22T17%3A06%3A53Z%22%7D%7D%5D%7D
Ikegame, K., Kaida, K., Fukunaga, K., Osugi, Y., Yoshihara, K., Yoshihara, S., Ishii, S., Fujino, S., Yamashita, T., Mayumi, A., Maruyama, S., Teramoto, M., Inoue, T., Okada, M., Tamaki, H., Ogawa, H., & Fujimori, Y. (2020). Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study. Bone Marrow Transplantation, 1–14. https://doi.org/10.1038/s41409-020-0980-8 Cite
